Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster presentation 1

911 - Mutations of KRAS/NRAS/BRAF in cetuximab-resistant metastatic CRC patients


19 Dec 2015


Poster presentation 1


Yen-Jung Lu


Annals of Oncology (2015) 26 (suppl_9): 42-70. 10.1093/annonc/mdv523


Y. Lu1, T.K. Thiam1, S.J. Chen1, H.C. Hsu2

Author affiliations

  • 1 Act Genomics, ACT Genomics, 11494 - Taipei/TW
  • 2 Division Of Hematology‑oncology, Chang Gung Memorial Hospital-Linkou, 333 - Taoyuan/TW


Abstract 911


Although patients with metastatic colorectal cancer (mCRC) bearing KRAS-exon2-wild-type could benefit from cetuximab treatment, ∼ 45% of these patients were refractory to such a therapy. This study aims to identify additional genetic markers that can enhance the prediction of the cetuximab treatment response.


53 mCRC patients with wild-type KRAS exon2 were treated with cetuximab/irinotecan-based chemotherapy in first-line or third-line setting. Formalin-fixed paraffin-embedded samples obtained from primary tumor of all subjects were analyzed for the mutational status of 10 genes in the EGFR pathway using next-generation sequencing technology.


We detected KRAS (exon 3 and 4) mutations in 5 patients, NRAS mutations in 4 patients, and BRAF mutations in 6 patients. Except for 1 patient with an NRAS mutation who was a responder, all other patients harboring KRAS, NRAS, or BRAF mutations are non-responders, indicating the predictive role of these genetic mutations for poor cetuximab responsivness. The Kaplan-Mirer analysis revealed that patients with KRAS or BRAF mutations have a significantly shorter progress-free survival.


Our results suggest that genetic testing for KRAS in combination with NRAS and BRAF provides a stronger predictive power and should be implemented to improve the response rate of cetuximab for mCRC patients.

Clinical trial identification


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings